Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Sanguine, Mayo Clinic Agreement Furthers Personalized Medicine

By Drug Discovery Trends Editor | April 17, 2014

Sanguine Logo (Source: PRNewsFoto/Sanguine)Sanguine, a technology company enabling personalized medical research for the development of new and effective treatments, announced an agreement with Mayo Clinic Bioservices. Under this agreement, Mayo Clinic Bioservices will process, store and ship biospecimens that Sanguine has collected for clients developing new therapies. This will dramatically increase Sanguine’s capacity and scalability, allowing the company to serve more clients simultaneously.
 
Mayo Clinic Bioservices will provide integrated laboratory services that are vital to basic, translational and epidemiological research, including specimen accessioning, processing, nucleic acid extraction, specimen tracking, storage and shipping. Mayo Clinic Bioservices is a new service from the Mayo Clinic Center for Individualized Medicine with locations at Mayo’s Minnesota, Florida, and Arizona campuses.
 
“We are excited about the pilot project with Mayo, not only because it increases the scalability of our business, but also because it allows individuals that have been on our waiting list to participate in the research and development of new treatments,” said Brian Neman, CEO of Sanguine. “Mayo Clinic Bioservices has tremendous infrastructure and processing capacity that will meet our existing needs while also offering the potential for future expansion.”
 
Sanguine bridges the gap between individuals interested in participating in biomedical research and the companies and institutions developing new clinical treatments. Sanguine’s products and services offer transparency, convenience and participant engagement, as the company works to digitize and streamline the biomedical research enrollment process. Examples include electronic informed consent, remote screening, and automated scheduling of home phlebotomy appointments.
 
The company’s latest product is a mobile application that connects study phlebotomists with potential research participants. The app allows phlebotomists to enter a personalized schedule and then offers available blood-donation times to interested study participants. The app has attracted a network of participants in more than 16 cities across the United States, and interest in this approach continues to grow.
 
“In addition to allowing us to better serve our existing network of participating individuals, this collaboration allows Sanguine to provide more comprehensive services for our clients, which already include 20 of the top 40 pharmaceutical and biotechnology companies,” Neman said. “Our primary goal is to facilitate development of new therapeutic options for patients and their care providers by linking individuals interested in making a difference with the companies and institutions that develop new treatments. This collaboration with Mayo Clinic is another step in making that process more efficient and thereby getting new therapies to patients.” 
 
Date: April 16, 2014 
Source: Sanguine

Filed Under: Drug Discovery

 

Related Articles Read More >

Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority
Portrait photo of Pfizer EVP and Medtronic board member Lidia Fonseca
Medtronic appoints Pfizer EVP as independent board director

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50